Unwanted reactions to modifying antirheumatic drugs

To specify causes of discontinuation of the disease-modifying antirheumatic drugs (DMAD) used in rheumatoid arthritis (RA) by the results of special questionnaire survey. The study included 298 RA patients treated in the Institute of Rheumatology (34 males and 264 females aged 18-82, mean age 54.6%,...

Full description

Saved in:
Bibliographic Details
Published inTerapevtic̆eskii arhiv Vol. 77; no. 5; p. 72
Main Authors Evsikova, M D, Muraviev, Iu V
Format Journal Article
LanguageRussian
Published Russia (Federation) 2005
Subjects
Adolescent
Adult
Aged
Aged, 80 and over
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Drug Evaluation
Female
Humans
Male
Middle Aged
Rheumatic Diseases - drug therapy
Surveys and Questionnaires
Online AccessGet more information

Cover

More Information
Summary:To specify causes of discontinuation of the disease-modifying antirheumatic drugs (DMAD) used in rheumatoid arthritis (RA) by the results of special questionnaire survey. The study included 298 RA patients treated in the Institute of Rheumatology (34 males and 264 females aged 18-82, mean age 54.6%, duration of the disease 1 to 38 years, mean 10.7 years) who responded to questioning. The following DMAD were used: metotrexate (n = 137), sulfasalasine (n = 49), aminoquinoline drugs (n = 33), chlorbutin (n = 19), azathioprin (n = 13), tauredon (n = 11), cyclophosphamide (n = 5). The drugs were discontinued due to unwanted effects in 50, 10, 46, 9, 4, 3, 3 (methotrexate, sulfasalasin, aminoquinolines, chlorbutin, azathioprin, Ag salts, cyclophosphamide, respectively). Cyclophosphamide and chlorbutin appeared most toxic, while sulfasalasine and aminoquinolines were found least effective. DMAD discontinuation rate ranges from 12.1% (aminoquinolines) to 60% (cyclophosphamide), mean 31.1%.
ISSN:0040-3660